🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Biocon Limited BIOCON NIFTY_MIDNSEPHARMA

Healthcare · Biotechnology · India
https://www.biocon.com
Company Profile ↓
₹397.40
+12.11% 1Y
Mkt Cap₹64,414.87 Cr
P/E140.92
P/B2.03
Div. Yield0.11%
52W High₹440.70
52W Low₹338.50
Book Value₹209.96
EPS (TTM)₹2.82

Company Overview

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 15.3% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹16,779.90 Cr (+11.5% YoY); net profit ₹385.60 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.5%, earnings -62.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.3%, profit CAGR -5.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.35%
1 Year:11.48%

Compounded Profit Growth

5 Years:-5.90%
1 Year:-61.95%

Stock Price Performance

1 Year:+12.11%
6 Months:+1.84%
3 Months:-4.44%
1 Month:-8.98%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 58% of range
₹338.50 ₹440.70
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)33.55 · Neutral
Price Performance
1M-8.98%
3M-4.44%
6M+1.84%
1Y+12.11%
Valuation vs Sector

P/E of 140.92 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 140.9.
  • Earnings shrank at -5.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
140.92
Industry PE
41.64
Forward P/E
34.38
PEG Ratio
-
Book Value
₹209.96
Price to Book
2.03
P/S
4.01
EV/EBITDA
24.87
Dividend Yield
0.11%

Growth (CAGR)

Revenue 5Y
15.35%
Profit 5Y
-5.90%
Revenue (YoY)
11.48%
Earnings (YoY)
-61.95%

Profitability & Returns

ROCE
2.85%
ROE
1.13%
ROA
0.61%
Profit Margin
2.30%
Op Margin
10.26%
Gross Margin
66.06%
EPS (Latest Qtr)
₹0.87
EPS (TTM)
₹2.82

Balance Sheet & Liquidity

Debt/Equity
0.45
Quick Ratio
0.79
Current Ratio
1.22
Debt
₹15,434.10 Cr
Total Assets
₹63,650.60 Cr
Current Assets
₹17,179.80 Cr
Working Capital
₹3,110.60 Cr

Ownership

Promoter Holding
48.12%
Chg in Prom Hold
-5.65%
FII / Inst Holding
32.49%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹64,414.87 Cr
Total Revenue (TTM)
₹16,779.90 Cr
EBITDA
₹3,369.40 Cr
Free Cash Flow
₹82.30 Cr
Operating Cash Flow
₹1,994.00 Cr
Shares Outstanding
₹162.09 Cr
Gross Margin
66.06%
Payout Ratio
17.73%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BIOCON Biocon Limited NIFTY_MIDNSEPHARMA 397.40 140.92 ₹64,414.87 Cr 0.11% 2.85% 1.13% 15.35% -5.90%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 3,774.00 Cr3,423.00 Cr3,462.00 Cr3,954.00 Cr3,917.00 Cr3,433.00 Cr3,590.00 Cr--3,910.10 Cr4,262.50 Cr4,173.00 Cr4,484.30 Cr4,291.80 Cr
Cost of Revenue ---------1,405.10 Cr1,547.00 Cr1,339.30 Cr1,399.30 Cr1,467.60 Cr
Gross Profit -------2,462.10 Cr2,885.20 Cr---3,085.00 Cr2,824.20 Cr
Operating Expenses 2,817.00 Cr2,741.00 Cr2,745.00 Cr3,051.00 Cr3,004.00 Cr2,812.00 Cr2,905.00 Cr--2,193.90 Cr2,353.10 Cr2,515.50 Cr2,578.10 Cr2,524.40 Cr
Operating Income 593.00 Cr323.00 Cr328.00 Cr489.00 Cr506.00 Cr215.00 Cr265.00 Cr--311.10 Cr362.40 Cr318.20 Cr506.90 Cr299.80 Cr
EBITDA 957.00 Cr681.00 Cr717.00 Cr903.00 Cr913.00 Cr620.00 Cr685.00 Cr--828.60 Cr916.50 Cr657.40 Cr992.40 Cr888.20 Cr
Interest Expense 249.00 Cr233.00 Cr248.00 Cr267.00 Cr227.00 Cr236.00 Cr226.00 Cr--276.70 Cr272.20 Cr209.90 Cr231.50 Cr213.20 Cr
Pretax Income 497.00 Cr184.00 Cr214.00 Cr808.00 Cr319.00 Cr1,146.00 Cr98.00 Cr--96.90 Cr171.30 Cr-67.80 Cr247.50 Cr127.60 Cr
Tax Provision 84.49 Cr34.96 Cr40.66 Cr56.56 Cr95.70 Cr286.50 Cr70.56 Cr--7.70 Cr38.50 Cr-16.00 Cr48.90 Cr-9.20 Cr
Net Income 414.00 Cr149.00 Cr173.00 Cr753.00 Cr223.00 Cr862.00 Cr27.00 Cr--31.40 Cr84.50 Cr143.80 Cr125.90 Cr141.10 Cr
Diluted EPS 2.610.841.055.501.135.49-0.13--0.260.651.070.790.87

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,090.00 Cr3,347.00 Cr3,891.00 Cr4,123.00 Cr5,514.00 Cr6,300.00 Cr7,143.00 Cr-10,934.10 Cr14,195.80 Cr15,052.20 Cr16,779.90 Cr
Cost of Revenue --------3,666.80 Cr4,906.60 Cr5,198.00 Cr5,694.80 Cr
Gross Profit --------7,267.30 Cr9,289.20 Cr9,854.20 Cr11,085.10 Cr
Operating Expenses 2,394.00 Cr2,957.00 Cr2,912.00 Cr3,294.00 Cr4,121.00 Cr4,696.00 Cr5,562.00 Cr-5,640.20 Cr7,854.70 Cr8,228.30 Cr9,363.00 Cr
Operating Income 475.00 Cr141.00 Cr703.00 Cr444.00 Cr946.00 Cr1,052.00 Cr866.00 Cr-1,627.10 Cr1,434.50 Cr1,625.90 Cr1,722.10 Cr
EBITDA 696.00 Cr390.00 Cr980.00 Cr829.00 Cr1,394.00 Cr1,604.00 Cr1,581.00 Cr-2,429.20 Cr4,068.40 Cr4,461.30 Cr3,369.40 Cr
Interest Expense 9.00 Cr29.00 Cr26.00 Cr62.00 Cr71.00 Cr65.00 Cr58.00 Cr-419.00 Cr974.40 Cr887.70 Cr964.80 Cr
Pretax Income 624.00 Cr751.00 Cr850.00 Cr610.00 Cr1,215.00 Cr1,186.00 Cr1,068.00 Cr-897.10 Cr1,525.20 Cr1,886.60 Cr447.90 Cr
Tax Provision 93.60 Cr142.69 Cr161.50 Cr158.60 Cr206.55 Cr320.22 Cr224.28 Cr-254.10 Cr227.40 Cr457.20 Cr79.10 Cr
Net Income 528.00 Cr609.00 Cr688.00 Cr453.00 Cr1,003.00 Cr871.00 Cr846.00 Cr-462.70 Cr1,022.50 Cr1,013.30 Cr385.60 Cr
Diluted EPS 4.144.595.103.107.546.246.17-3.878.548.462.82

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 6,375.00 Cr8,458.00 Cr9,394.00 Cr9,990.00 Cr12,192.00 Cr14,414.00 Cr18,490.00 Cr-52,042.80 Cr56,070.70 Cr58,797.30 Cr63,650.60 Cr
Current Assets --------12,334.00 Cr15,179.20 Cr16,286.20 Cr17,179.80 Cr
Cash & Equivalents --------1,323.20 Cr1,233.40 Cr3,226.70 Cr2,416.00 Cr
Inventory --------4,243.70 Cr4,943.90 Cr4,931.10 Cr6,085.70 Cr
Receivables --------3,573.20 Cr6,230.60 Cr5,487.90 Cr5,986.80 Cr
Total Liabilities --------29,554.00 Cr30,795.90 Cr31,084.80 Cr27,029.10 Cr
Current Liabilities --------8,510.70 Cr15,358.80 Cr14,333.80 Cr14,069.20 Cr
Long Term Debt --------15,290.50 Cr12,932.40 Cr12,405.40 Cr10,746.30 Cr
Total Debt 1,117.00 Cr2,478.00 Cr2,302.00 Cr2,264.00 Cr2,422.00 Cr2,715.00 Cr4,481.00 Cr-18,018.80 Cr16,276.70 Cr18,362.00 Cr15,434.10 Cr
Total Equity 3,271.00 Cr4,034.00 Cr4,838.00 Cr5,181.00 Cr6,098.00 Cr6,706.00 Cr7,627.00 Cr-17,866.90 Cr19,783.70 Cr21,644.00 Cr34,031.80 Cr
Shares Outstanding --------120.06 Cr120.06 Cr120.06 Cr162.09 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 211.00 Cr371.00 Cr640.00 Cr662.00 Cr1,155.00 Cr1,283.00 Cr1,160.00 Cr-1,852.50 Cr2,953.90 Cr4,061.20 Cr1,994.00 Cr
Investing Cash Flow -491.00 Cr-1,138.00 Cr-510.00 Cr-684.00 Cr-703.00 Cr-1,505.00 Cr-3,651.00 Cr--14,281.80 Cr-1,004.50 Cr-234.10 Cr-2,082.10 Cr
Financing Cash Flow 186.00 Cr1,068.00 Cr-178.00 Cr-240.00 Cr-242.00 Cr388.00 Cr2,564.00 Cr-13,048.70 Cr-2,332.70 Cr-1,854.00 Cr-923.60 Cr
Capital Expenditure -838.00 Cr-617.00 Cr-608.00 Cr-913.00 Cr-1,492.00 Cr-1,829.00 Cr-1,737.00 Cr--1,726.30 Cr-1,931.60 Cr-2,343.30 Cr-1,911.70 Cr
Free Cash Flow -627.00 Cr-246.00 Cr32.00 Cr-251.00 Cr-337.00 Cr-546.00 Cr-577.00 Cr-126.20 Cr1,022.30 Cr1,717.90 Cr82.30 Cr
Net Change in Cash -94.00 Cr300.00 Cr-47.00 Cr-261.00 Cr210.00 Cr165.00 Cr72.00 Cr-619.40 Cr-383.30 Cr1,973.10 Cr-1,011.70 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------66.5%65.4%65.5%66.1%
Operating Margin % 15.4%4.2%18.1%10.8%17.2%16.7%12.1%-14.9%10.1%10.8%10.3%
Net Margin % 17.1%18.2%17.7%11.0%18.2%13.8%11.8%-4.2%7.2%6.7%2.3%
ROE % 16.1%15.1%14.2%8.7%16.4%13.0%11.1%-2.6%5.2%4.7%1.1%
ROCE % --------3.7%3.5%3.7%3.5%

Shareholding Pattern

Insiders
48.12%
Institutions
32.49%
Public Float
62.62%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIOCON

Yahoo Finance hu, 06 Aug 2026

Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ...

Biocon Ltd (BOM:532523) delivers robust Q1 FY27 with strong biosimilar and generics growth, offsetting Syngene's decline.

Yahoo Finance Mon, 03 Aug 2026

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

BENGALURU, India & BRIDGEWATER, N.J., August 03, 2026--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg, Used to Treat Various Types of Ophthalmology Conditions…

Yahoo Finance Wed, 01 Jul 2026

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 …

Yahoo Finance Sat, 09 May 2026

Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and ...

Biocon Ltd (BOM:532523) reports robust revenue growth driven by biosimilars, strategic debt reduction, and key market expansions despite external challenges.

Yahoo Finance Sun, 09 Aug 2026

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump On Margin Focus And Peer Valuation Cues

Biocon’s updated valuation work now points to a fair value price target of ₹429.67, compared with the earlier figure of ₹416.53. Recent research on peers in life sciences and diagnostics highlights how analysts are weighing profitability pl…

Yahoo Finance hu, 09 Jul 2026

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

BENGALURU, India & BRIDGEWATER, N.J., July 09, 2026--Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectivene…

BIOCON — Frequently Asked Questions

What is the current share price of Biocon Limited (BIOCON)?

As of 2026-09-08 04:53 IST, Biocon Limited (BIOCON) trades at ₹397.40 on NSE. Its 52-week range is ₹338.50 to ₹440.70.

What is the market capitalisation of BIOCON?

Biocon Limited (BIOCON) has a market capitalisation of ₹64,414.87 Cr on NSE.

What is the P/E ratio of BIOCON?

BIOCON trades at a trailing price-to-earnings (P/E) ratio of 140.92. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.03.

Does BIOCON pay a dividend?

Biocon Limited (BIOCON) currently offers a dividend yield of 0.11%.

What is the return on equity (ROE) of BIOCON?

BIOCON has a return on equity (ROE) of 1.13%. Its return on capital employed (ROCE) is 2.85%.

Is BIOCON a good stock to buy?

This page provides a data-driven analysis of Biocon Limited (BIOCON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space